Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The most effective method to Guarantee Simple Availability in Seniors' SUVs - 2Navy-Marine Corps Relief Society provides emergency grants to families displaced by Iran war
- 3Pick Your Favored pizza beating
- 4In these U.S. groups, deaths now exceed births. What’s happening?
- 5She was moments away from giving birth. The hospital discharged her
- UN warns civil liberties under threat due to war in Middle East
- Go on A Careful spending plan: Modest Objections for Your List of must-dos
- These 2 companies are teaming up to offer insurance for space debris strikes on satellites
- Gunmen open fire near Israeli consulate in Istanbul in possible ISIS-linked attack
- What's your biological age? Experts explain the benefits and risks of at-home tests
- These are the Fastest Italian Sports Cars
- Tesla Stock Hasn’t Looked This Cheap in a While
- 8 key takeaways from Savannah Guthrie's 'Today' interview on the disappearance of her mother
- How a rare drug made from scientists' blood saves babies from botulism
